MedInCell Shares Drop 2.84% But Still Up 54% Year-Over-Year
Shares of the biotech company based in Montpellier fell early in the week, in a declining Parisian market. The CAC 40 is down 0.51% during the session and the SBF 120 loses 0.40%. However, the stock remains up over 54% for the year.
MedInCell falls 2.84% to €23.98 at midday, after closing at €24.68 in the last session. This movement continues the 3.55% decline observed last Thursday, April 30, which itself followed a rebound of 5.51% the day before. Over seven days, the performance remains positive at 3.54%. The session context is heavy. The CAC 40 is at 8,073.71 points (-0.51%) and the SBF 120 at 6,133.83 points (-0.40%). In the background, the ECB kept its key interest rates unchanged on April 30, signaling an intensification of upward risks on inflation and downward risks on growth, linked to the conflict in the Middle East and rising energy prices. Brent is trading around $108.36 a barrel. These macro elements remain a backdrop to the session, with no direct link established with the biotech's movement.
A Busy Schedule with the R&D Day on May 12 in Sight
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The stock price moves in the upper part of the Bollinger Bands, at 66% of the width, between €21.31 and €25.35. The resistance at €25.12 remains immediately close, just over 4% from the current price. The RSI at 49 indicates a balance between buyers and sellers, without excess in either direction. The stock has fallen below its MM200 at €24.03; it had moved above this level at the beginning of April but had already lost this level by mid-April. The short-term agenda is packed. The company will hold a live R&D day on May 12, 2026, before the publication of annual results (fiscal year April 2025 - March 2026) on June 16. At the last semi-annual publication (April-September 2025), MedInCell indicated it expected an acceleration of revenues in the coming years with olanzapine LAI, for which the NDA application has been filed. Teva has also raised its 2025 net sales forecast for UZEDY® from $160 million to $190-200 million. The May 12 event is the next scheduled point by the company.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
